Polymed Biopharmaceuticals Announces Out-Licensing IRAK4 PROTAC HPB-143 for Aut...
Hangzhou, China and Cambridge, Massachusetts – [Feb 18, 202...
Learn More
Poster from Polymed at 6th Annual Targeted Protein Degradation Summit in Boston...
From October 30 to November 2, the 6th Annual Targeted Prot...
Learn More
Seminar by Dr Jason Xiang at Boston SEAL Club
On Feb 4, 2023, Dr. Jason Shaoyun Xiang, founder and CEO of...
Learn More
Polymed Biotech completed a new round of financing joint by Shaanxi Junying Jia...
On December 12, 2022, Hangzhou Polymed Biopharmaceuticals C...
Learn More
Polymed Biotech commences a new round of financing for developing PROTAC drugs
On November 28, 2022, Hangzhou Polymed Biopharmaceuticals C...
Learn More
Polymed raised RMB 50 million in pre-A round financing
Polymed Biopharmaceuticals, Inc., recently concluded an RMB...
Learn More
Arbella Therapeutics and Polymed Biopharmaceuticals announce exclusive collabor...
Arbella Therapeutics, LLC, and Hangzhou Polymed Biopharmace...
Learn More
Polymed Biopharma making progress in new drug discovery on PROTAC platform
Polymed Biopharma recently submitted two patent application...
Learn More
Polymed obtains pre-A round investment from Sundoc Pharmaceutical
Polymed Biopharmaceuticals, Inc., has closed an RMB 15 mill...
Learn More